Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)

0.6058
Delayed Data
As of 3:59pm ET
 -0.0378 / -5.87%
Today’s Change
0.58
Today|||52-Week Range
8.50
-87.25%
Year-to-Date
uniQure (QURE) Up on Safety Data From Huntington's Disease Study
10:30am / Zacks.com - Paid Partner Content
Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why
Jun 15 / Zacks.com - Paid Partner Content
Precision BioSciences' (DTIL) Stock Up This Week: Here's Why
Jun 23 / Zacks.com - Paid Partner Content
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod
Jun 14 / Zacks.com - Paid Partner Content
Apellis (APLS) Expands Deal for Targeted Complement Therapies
Jun 23 / Zacks.com - Paid Partner Content
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
Jun 14 / Zacks.com - Paid Partner Content
Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation
Jun 21 / Zacks.com - Paid Partner Content
Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development
Jun 13 / Zacks.com - Paid Partner Content
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
Jun 20 / Zacks.com - Paid Partner Content
Cogent (COGT) Surges on Robust Data from Mastocytosis Study
Jun 13 / Zacks.com - Paid Partner Content